Medartis Holding Valuation
Is MED undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MED when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MED (CHF56.6) is trading above our estimate of fair value (CHF25.5)
Significantly Below Fair Value: MED is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MED?
Other financial metrics that can be useful for relative valuation.
What is MED's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CHF 768.68m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.5x |
Enterprise Value/EBITDA | 29.5x |
PEG Ratio | 3.7x |
Price to Sales Ratio vs Peers
How does MED's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3.1x | ||
MEDX medmix | 0.9x | 4.0% | CHF 424.2m |
METN Metall Zug | 1.2x | -26.8% | CHF 544.5m |
MOVE Medacta Group | 5x | 12.0% | CHF 2.5b |
SOON Sonova Holding | 5.2x | 6.2% | CHF 18.9b |
MED Medartis Holding | 3.5x | 13.7% | CHF 768.7m |
Price-To-Sales vs Peers: MED is expensive based on its Price-To-Sales Ratio (3.5x) compared to the peer average (3.1x).
Price to Earnings Ratio vs Industry
How does MED's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Sales vs Industry: MED is good value based on its Price-To-Sales Ratio (3.5x) compared to the European Medical Equipment industry average (3.8x).
Price to Sales Ratio vs Fair Ratio
What is MED's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 3.5x |
Fair PS Ratio | 6.2x |
Price-To-Sales vs Fair Ratio: MED is good value based on its Price-To-Sales Ratio (3.5x) compared to the estimated Fair Price-To-Sales Ratio (6.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | CHF 55.20 | CHF 98.20 +77.9% | 10.0% | CHF 110.00 | CHF 85.40 | n/a | 4 |
Oct ’25 | CHF 57.20 | CHF 98.20 +71.7% | 10.0% | CHF 110.00 | CHF 85.40 | n/a | 4 |
Sep ’25 | CHF 63.50 | CHF 98.20 +54.6% | 10.0% | CHF 110.00 | CHF 85.40 | n/a | 4 |
Aug ’25 | CHF 75.00 | CHF 98.98 +32.0% | 9.5% | CHF 110.00 | CHF 85.40 | n/a | 4 |
Jul ’25 | CHF 68.40 | CHF 98.98 +44.7% | 9.5% | CHF 110.00 | CHF 85.40 | n/a | 4 |
Jun ’25 | CHF 76.50 | CHF 98.98 +29.4% | 9.5% | CHF 110.00 | CHF 85.40 | n/a | 4 |
May ’25 | CHF 80.20 | CHF 98.98 +23.4% | 9.5% | CHF 110.00 | CHF 85.40 | n/a | 4 |
Apr ’25 | CHF 89.40 | CHF 98.85 +10.6% | 9.7% | CHF 110.00 | CHF 84.90 | n/a | 4 |
Mar ’25 | CHF 72.70 | CHF 96.78 +33.1% | 11.7% | CHF 110.00 | CHF 81.80 | n/a | 4 |
Feb ’25 | CHF 73.90 | CHF 101.77 +37.7% | 8.2% | CHF 110.00 | CHF 90.30 | n/a | 3 |
Jan ’25 | CHF 84.00 | CHF 101.77 +21.2% | 8.2% | CHF 110.00 | CHF 90.30 | n/a | 3 |
Dec ’24 | CHF 73.20 | CHF 101.77 +39.0% | 8.2% | CHF 110.00 | CHF 90.30 | n/a | 3 |
Nov ’24 | CHF 71.40 | CHF 101.77 +42.5% | 8.2% | CHF 110.00 | CHF 90.30 | n/a | 3 |
Oct ’24 | CHF 84.10 | CHF 132.65 +57.7% | 31.9% | CHF 175.00 | CHF 90.30 | CHF 57.20 | 2 |
Sep ’24 | CHF 88.50 | CHF 113.43 +28.2% | 38.8% | CHF 175.00 | CHF 75.00 | CHF 63.50 | 3 |
Aug ’24 | CHF 81.00 | CHF 110.13 +36.0% | 43.0% | CHF 175.00 | CHF 63.00 | CHF 75.00 | 3 |
Jul ’24 | CHF 76.70 | CHF 110.13 +43.6% | 43.0% | CHF 175.00 | CHF 63.00 | CHF 68.40 | 3 |
Jun ’24 | CHF 74.30 | CHF 119.00 +60.2% | 47.1% | CHF 175.00 | CHF 63.00 | CHF 76.50 | 2 |
May ’24 | CHF 74.10 | CHF 119.00 +60.6% | 47.1% | CHF 175.00 | CHF 63.00 | CHF 80.20 | 2 |
Apr ’24 | CHF 71.40 | CHF 119.00 +66.7% | 47.1% | CHF 175.00 | CHF 63.00 | CHF 89.40 | 2 |
Mar ’24 | CHF 70.40 | CHF 126.50 +79.7% | 38.3% | CHF 175.00 | CHF 78.00 | CHF 72.70 | 2 |
Feb ’24 | CHF 76.50 | CHF 126.50 +65.4% | 38.3% | CHF 175.00 | CHF 78.00 | CHF 73.90 | 2 |
Jan ’24 | CHF 82.00 | CHF 126.50 +54.3% | 38.3% | CHF 175.00 | CHF 78.00 | CHF 84.00 | 2 |
Dec ’23 | CHF 90.40 | CHF 126.50 +39.9% | 38.3% | CHF 175.00 | CHF 78.00 | CHF 73.20 | 2 |
Nov ’23 | CHF 77.80 | CHF 124.00 +59.4% | 32.1% | CHF 175.00 | CHF 78.00 | CHF 71.40 | 3 |
Oct ’23 | CHF 68.00 | CHF 124.00 +82.4% | 32.1% | CHF 175.00 | CHF 78.00 | CHF 84.10 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.